Molecular Partners AG (NASDAQ: MOLN) — Company Overview, News & Financial Data
Molecular Partners AG is a biotech firm advancing innovative therapies for serious diseases using proprietary DARPin technology.
Molecular Partners AG
Molecular Partners AG ADR (SWX:MOLN), (NASDAQ:MOLN) is a biotech firm focused on the discovery, development, and commercialization of innovative therapies to treat serious diseases, including oncology, ophthalmology, and virology. Leveraging its proprietary DARPin (Designed Ankyrin Repeat Proteins) technology, the company aims to develop drugs that can improve upon the efficacy, safety, and convenience of existing treatments. Molecular Partners is passionate about harnessing the power of its technology platform to create medicines that can make a significant difference in patients' lives. With a pipeline that includes both wholly owned programs and collaborations with major pharmaceutical companies, the company is committed to pushing the boundaries of science to bring new solutions to market. Molecular Partners' objectives center on advancing its clinical projects through development stages efficiently and establishing strategic partnerships to enhance and accelerate its drug development efforts.
Snapshot
Operations
Products and/or services of Molecular Partners AG
- DARPin Therapeutics - a new class of custom-built protein therapies designed for high specificity and potency in various diseases, including cancer and eye diseases.
- Abicipar - a novel, long-acting DARPin for the treatment of neovascular age-related macular degeneration, offering less frequent injections compared to current standards.
- COVID-19 Antiviral Program - development of antiviral DARPins targeting multiple sites of the virus to prevent infection and spread, aiming for high efficacy against SARS-CoV-2.
- MP0250 - a multi-DARPin targeting VEGF, HGF, and Fc?Rs for the treatment of multiple myeloma, aiming to inhibit tumor growth and spread.
- MP0310 (AMG 506) - a FAP x 4-1BB bispecific DARPin designed to stimulate the immune system only within the tumor microenvironment, reducing systemic side effects.
- Proprietary DARPin Platform - offering partnership opportunities for the discovery and development of novel therapeutics across a broad range of diseases and therapeutic areas.
Molecular Partners AG executive team
- Patrick AmstutzCo-Founder, CEO, Member of Management Board & Director
- Michael Tobias StumppCo-Founder, Executive VP of Projects & Member of Management Board
- Robert HendriksSenior VP of Finance & Member of Management Board
- Alexander ZurcherCOO & Member of Management Board
- Renate GloggnerExecutive VP of People & Community and Member of Management Board
- Philippe LegenneChief Medical Officer & Member of the Management Board
- Martin SteegmaierChief Scientific Officer & Member of the Management Board
- Michael PitznerExecutive VP of Partnering & General Counsel
- Pamela A. TrailStrategic Consultant
- Daniel SteinerSenior Vice President of Targeted Radio Therapeutics
Latest news about Molecular Partners AG
Molecular Partners plans cuts of up to 44% as focus shifts
United StatesMolecular Partners advances cancer pipeline with CHF 67.9 million cash
United StatesMolecular Partners reports progress in TACTIC trial
United StatesMolecular Partners reports pipeline progress in radiopharmaceutical programs
United States
Key financials
Reported results for Molecular Partners AG , in CHF.
- Market cap
- 145.9M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.7
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -58.1M | -61.7M | |
| 5M | -61.2M | -54M | |
| 7M | -61.1M | -62M | |
| 189.6M | 116.6M | 117.9M |